Official Title
Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
Brief Title
Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
Protocol ID
NCT03712566
Lead Sponsor
University Health Network, Toronto
Brief Summary
This is prospective research study which will include patients with recurrent or
metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal
starting on first-line platinum based chemotherapy or any line of immunotherapy
treatment.This study aims to characterize the dynamic changes in genomic, epigenetic,
immune profiling and imaging data during treatment with systemic therapy. Patients will
have archived tumor samples requested as well as blood samples collected at up to four
time points to analyze these changes. Imaging data will be derived from patients' routine
CT scans before and after treatment.
Study Period
Enrollment Count
39 participants
Eligibility Criteria
Inclusion Criteria:
1. Patients with a histological or cytological diagnosis of Squamous Cell Cancer of the
head and neck, esophagus or anal canal who have radiologically confirmed recurrent
or metastatic disease.
2. Patients must be of adequate fitness, ECOG 0-1 for systemic therapy, with either
standard chemotherapy, immunotherapy or within the context of a clinical trial.
3. Patients must be commencing on a new treatment at time of consent, this can be first
line platinum based chemotherapy, or immunotherapy, any line.
4. Patients must be ≥ 18 years old.
5. Patients must have provided voluntary written informed consent.
Exclusion Criteria:
None
Filters
Cancer
Esophagus Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Anal Canal Squamous Cell Carcinoma
Metastatic Cancer
ACTIVE_NOT_RECRUITING
ADULT
OLDER_ADULT